About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379206 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/23/2021.
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Our Science

fedratinib (JAK2 Inhibitor)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Proposed Mechanism of Action

Fedratinib is an oral small molecule kinase inhibitor with higher selectivity for JAK2 over other JAK family members, including JAK1, JAK3 and tyrosine kinase 2.1-3 Myelofibrosis is a life-threatening myeloproliferative neoplasm (MNP) that occurs due to the proliferation of mutant hematopoietic stem and progenitor cells and can be caused by alterations in the JAK/STAT pathway.4,5 Approximately 60?65% of patients with primary myelofibrosis have a mutation in JAK2, typically JAK2V617F.5 An additional 20-30% of patients with primary myelofibrosis have abnormalities in markers mutant Calreticulin or the thrombopoietin receptor, also known as the myeloproliferative leukemia protein (MPL), which also signal through the JAK2/STAT pathway.5 Preclinical studies have suggested that fedratinib may inhibit both mutant and wild-type JAK2, thus blocking abnormal hyperactive JAK/STAT signaling and inhibiting proliferation in hematopoietic stem cells with or without mutations in JAK2.2,6,7

Fedratinib Proposed Mechanism of Action

Used under license, ?2019 Impact Biomedicines, Inc.